

Data Sharing Statement

| | | |
|---------------------|---|--|
| Article Info | https://dx.doi.org/10.21037/tlcr-23-643 | |
| Item | Question | Authors' Response (place "-" if not applicable) |
| 1 | Would you like to share data collected for your study to others? | Yes. |
| 2 | If not, would you like to share the reason for your decision? | - |
| 3 | What data in particular will be shared? | The survival data in particular will be shared, and we also found a correlation between PFS and PD-L1 expression status who received amivantamab in NSCLC E20I patients. |
| 4 | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | - |
| 5 | When will data availability begin? | From the publication date. |
| 6 | When will data availability end? | Two years within the publication date. |
| 7 | To whom will you share the data? | Medical oncologists who are interested in metastatic lung cancer. |
| 8 | For what type of analysis or purpose? | For analysis to evaluate the efficacy of amivantamab in E20I NSCLC patients in real-world setting. |
| 9 | How or where can the data/documents be obtained? | If you have any data you would like to obtain regarding this content, please contact me at pearl nod1234@gmail.com, and I will provide it if necessary. |
| 10 | Any other restrictions? | - |